• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Clene Announces New Chief Financial Officer Morgan Brown

    2/1/22 7:00:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email

    SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022.

    "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and debt financing transactions for strategic growth. His expertise in these areas will be critical to Clene as we look ahead to potential commercialization of our lead drug candidate, CNM-Au8, in ALS next year."

    Mr. Etherington continued, "As we welcome Morgan, we'd like to thank our outgoing CFO, Ted Jeong, for his invaluable leadership in guiding Clene through our public listing on the Nasdaq. Ted's depth of expertise in biotech venture capital and public equity financing has placed Clene on solid public-company footing. Ted will continue in a consultative role at Clene during the transition. We wish him the best in his future endeavors in healthcare venture capital fund management at SV Investment."

    Mr. Brown's extensive experience in executive finance roles includes four publicly traded life science companies, three as CFO, and the CFO of a privately-held clinical research organization. In his prior roles, Mr. Brown has participated in and led efforts to successfully evaluate, negotiate, and close transactions including equity and debt financings totaling over $1 billion and out-licensing of commercial stage asset transactions totaling $220 million. Mr. Brown has experience in sale-leaseback arrangements, facilities construction, and M&A activities. Since 2013, he has been Executive VP and CFO of Lipocine, Inc. based in Salt Lake City. Previously, he served as Executive VP and CFO at Innovus Pharmaceuticals and World Heart Corporation. He served as CFO and Senior VP at Lifetree Clinical Research; and VP, Finance and Treasurer at NPS Pharmaceuticals. He began his career at KPMG LLP, where he rose to Senior Audit Manager before departing for a career in various healthcare executive positions. Mr. Brown is a certified public accountant (CPA) in the State of Utah and earned his MBA from the University of Utah and BS in Accounting from Utah State University. Recognized for his financial leadership, he was chosen CFO of the Year by Utah Business Magazine in 2009 and CFO of the Year by Utah Technology Council in 2011. Mr. Brown has served on boards of numerous professional organizations.

    About Clene

    Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure, an underlying cause of many neurological diseases. Our lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is currently being evaluated in a Phase 2/3 registration trial in amyotrophic lateral sclerosis (ALS) and a Phase 2 trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.

    Forward-Looking Statements

    This press release contains "forward-looking statements" which are intended to be covered by the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Clene's actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant known and unknown risks and uncertainties, many of which are beyond Clene's control and could cause actual results to differ materially and adversely from expected results. Factors that may cause such differences include Clene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Clene's ability to achieve commercial success for its marketed products and drug candidates, if approved; Clene's ability to obtain and maintain protection of intellectual property for its technology and drugs; Clene's reliance on third parties to conduct drug development, manufacturing and other services; Clene's limited operating history and its ability to obtain additional funding for operations and to complete the licensing or development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on Clene's clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Clene's Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Clene's subsequent filings with the U.S. Securities and Exchange Commission. Clene undertakes no obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

    Media Contact

    Maggie Beller

    Russo Partners, LLC

    [email protected]

    +1-646-942-5631

    Investor Contact

    John Woolford

    Managing Director, Westwicke

    [email protected]

    +1-443-213-0506



    Get the next $CLNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLNN

    DatePrice TargetRatingAnalyst
    10/4/2022Outperform → Perform
    Oppenheimer
    7/18/2022$16.00Buy
    H.C. Wainwright
    5/2/2022$10.00Buy
    Canaccord Genuity
    9/28/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $CLNN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Clene Inc.

      10-Q - Clene Inc. (0001822791) (Filer)

      5/7/25 8:03:14 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Clene Inc. (0001822791) (Filer)

      5/7/25 8:02:01 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Clene Inc.

      424B5 - Clene Inc. (0001822791) (Filer)

      4/28/25 8:05:38 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Clene Inc.

      SC 13G/A - Clene Inc. (0001822791) (Subject)

      11/14/24 3:32:55 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Clene Inc.

      SC 13G - Clene Inc. (0001822791) (Subject)

      11/14/24 3:26:45 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Clene Inc.

      SC 13D/A - Clene Inc. (0001822791) (Subject)

      10/2/24 4:38:44 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

      Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker dataClene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL dataClene reported new data supporting the remyelination and neuronal repair associated with CNM-Au8® treatment in a late-breaking science session at the American Academy of Neurology (AAN) 2025 Annual MeetingClene released new data from a cross-reg

      5/7/25 8:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

      MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t

      4/16/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

      MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register

      4/15/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance

    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner General Resonance Llc sold $12,092 worth of shares (2,733 units at $4.42), decreasing direct ownership by 0.38% to 710,852 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      3/19/25 6:47:32 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wilcox Reed N

      4 - Clene Inc. (0001822791) (Issuer)

      2/28/25 4:24:28 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mosca Alison

      4 - Clene Inc. (0001822791) (Issuer)

      2/28/25 4:24:08 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Clene downgraded by Oppenheimer

      Oppenheimer downgraded Clene from Outperform to Perform

      10/4/22 8:58:30 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Clene with a new price target

      H.C. Wainwright initiated coverage of Clene with a rating of Buy and set a new price target of $16.00

      7/18/22 7:19:07 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Clene with a new price target

      Canaccord Genuity initiated coverage of Clene with a rating of Buy and set a new price target of $10.00

      5/2/22 9:11:11 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Matlin David J bought $438,458 worth of shares (92,307 units at $4.75), increasing direct ownership by 26% to 444,491 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      10/2/24 12:58:21 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Science Officer Mortenson Mark bought $97,432 worth of shares (20,512 units at $4.75), increasing direct ownership by 243% to 28,949 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      10/1/24 4:17:45 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Etherington Robert Dee bought $47,500 worth of shares (10,000 units at $4.75), increasing direct ownership by 33% to 40,149 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      10/1/24 4:17:06 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Leadership Updates

    Live Leadership Updates

    See more
    • Clene Appoints Neurology Expert to Executive Team

      SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Benjamin Greenberg, M.D., M.H.S. as Head of Medical.    An internationally recognized expert in treating disorders of the central nervous system, Dr. Greenberg brings extensive clinical and research experience to Clene as the company continues its development of CNM-Au8® as a potential treatment for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). "Dr. Green

      3/16/23 9:46:10 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Announces New Chief Financial Officer Morgan Brown

      SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. "Morgan joins the executive team at a pivotal time in Clene's growth," stated Clene's President and CEO, Rob Etherington. "He is a seasoned healthcare executive and public-company biopharma CFO, who has led the out-licensing of commercial stage assets and M&A transactions as well as numerous substantial equity and

      2/1/22 7:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors

      SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the appointment of Vallerie V. McLaughlin, MD, to its board as its seventh independent director. Dr. McLaughlin is the Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine, Associate Chief Clinical Officer for Cardiovascular Services of the University of Michigan Medical Group, Associate Chief, Division of Cardiovascular Medicine, and Director of the Pulm

      8/5/21 4:01:00 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Financials

    Live finance-specific insights

    See more
    • Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial

      The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeksPrespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results from the Phase 2 RESCUE-ALS trialClene will continue the open-label extension of CNM-Au8 in the Healey ALS Platform Trial and is in discussions with the Healey & AMG ALS Center to design and offer an Expanded Access Protocol (EAP) of CNM-Au8 30mg for eligible participants of closed regimens and othersClene is pursuing multiple paths, including ongoi

      10/3/22 8:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3

      SALT LAKE CITY, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) along with its subsidiaries "Clene" and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will report topline results of the CNM-Au8® regimen of the HEALEY ALS Platform Trial on Monday, Oct. 3. Clene's management team will host a conference call and webcast to discuss the results. Conference Call and Webcast DetailsTime and Date: 8:30 a.m. EDT on Oct. 3, 2022Investors: 1 (888) 660-6179 (toll-free) or 1 (929) 203-1946 (toll)Conference ID: 5318408Webcast Link A live audio

      9/30/22 4:12:25 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis

      CNM-Au8 met primary and secondary endpoints of Low Contrast Letter Acuity (LCLA) and modified Multiple Sclerosis Functional Composite (mMSFC) compared to placebo over 48 weeks in the mITT populationConsistent improvements favoring CNM-Au8 were seen across paraclinical biomarkers, providing physiological evidence for its potential neuroprotective and remyelinating effectsCNM-Au8 treatment was well-tolerated, and there were no significant safety findings reportedResults provide support to advance CNM-Au8 into Phase 3 clinical developmentClene to host a call and webcast at 7:30 am EDT today SALT LAKE CITY, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiarie

      8/15/22 7:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care